Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“UGT1A1 matters…
But what really determines outcomes is not genetics – it’s management.
Largest safety analysis of sacituzumab govitecan (n=969, NA/EU vs Asia):
- Grade ≥3 AEs: NA/EU 74%, Asia 78%.
- Discontinuation: NA/EU 5%, Asia 4%.
- Death: NA/EU 1%, Asia 3%.
NA/EU: 28 allele more common.
Asia: 6 allele more common.
Asia: higher neutropenia, anemia, leukopenia.
NA/EU: higher diarrhea, fatigue
Neutropenia peaks early, then declines. Diarrhea remains stable
Bottom line: Toxicity exists. But it is manageable.”
Title: Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia
Authors: H. S. Rugo, S. M. Tolaney, J. Cortés, F. Marmé, E. de Azambuja, B. Xu, J. Sohn, Y. Naito, T. Valdez, D. Gary, J. Zhu, C. Lai, A. Bardia
Read The Full Article
Other articles about Breast Cancer on OncoDaily.